Home > Insider Trading > Filing (0001127602-14-006501)

Filing Details

Accession Number:: 0001127602-14-006501
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-02-14 16:42:13
Reporting Period:: 2014-02-12

Filing Date:: 2014-02-14
Accepted Time:: 2014-02-14 16:42:13
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
875045	Biogen Idec Inc.	BIIB	Biological Products, (No Disgnostic Substances) (2836)	330112644

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1577061	Alfred Sandrock	Biogen Idec Inc. 225 Binney Street Cambridge MA 02142	Grp Svp, Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-02-12	792	$0.00	14,459	No	4	M	Direct
Common Stock	Disposition	2014-02-12	367	$323.04	14,092	No	4	F	Direct
Common Stock	Acquisiton	2014-02-12	7,740	$0.00	21,832	No	4	A	Direct
Common Stock	Disposition	2014-02-13	425	$316.42	21,407	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit	Disposition	2014-02-12	792	$0.00	792	$0.00
Common Stock	Restricted Stock Unit	Acquisiton	2014-02-12	4,000	$0.00	4,000	$0.00
Common Stock	Restricted Stock Unit	Acquisiton	2014-02-12	13,340	$0.00	13,340	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,381	2017-02-12	No	4	M	Direct
4,000	2017-02-12	No	4	A	Direct
13,340	2019-02-12	No	4	A	Direct

Footnotes

Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.
This represents the weighted average price for shares sold at a range between $316.01 (low) and $316.81 (high).
The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).
The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest each year for four years, beginning two years from the date of grant. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).